Literature DB >> 22065318

Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.

Matthew H G Katz1, Huamin Wang, Aparna Balachandran, Priya Bhosale, Christopher H Crane, Xuemei Wang, Peter W T Pisters, Jeffrey E Lee, Jean-Nicolas Vauthey, Eddie K Abdalla, Robert Wolff, James Abbruzzese, Gauri Varadhachary, Xavier Chopin-Laly, Chusilp Charnsangavej, Jason B Fleming.   

Abstract

OBJECTIVES: To determine the influence of neoadjuvant chemoradiation and standardized dissection of the superior mesenteric artery upon the oncologic outcome of patients with localized pancreatic adenocarcinoma.
METHODS: One hundred ninety-four patients with pancreatic adenocarcinoma who underwent pancreaticoduodenectomy between 2004 and 2008 were evaluated. The retroperitoneal dissection was performed directly along the superior mesenteric artery in all cases. A standard histopathologic protocol that measured the "superior mesenteric artery (SMA) margin distance" between cancer cells and the superior mesenteric artery was employed.
RESULTS: Seventy-six percent of patients received neoadjuvant chemoradiation. The SMA margin was positive in 4% of patients but an additional 22% of patients with a negative margin had a SMA margin distance of ≤1 mm. Preoperative CT images overestimated the SMA margin distance in 73% of cases. Patients who received chemoradiation had longer SMA margin distances than those who did not. Patients who received chemoradiation and had a SMA margin of >1 mm had the lowest recurrence rates. Administration of neoadjuvant chemoradiation and lower estimated blood loss were independently associated with longer progression-free survival on multivariate analysis.
CONCLUSIONS: Preoperative chemoradiation and meticulous dissection of the superior mesenteric artery maximize the distance between cancer cells and the SMA margin and may influence locoregional control.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065318     DOI: 10.1007/s11605-011-1748-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  33 in total

1.  Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer.

Authors:  A Wibe; P R Rendedal; E Svensson; J Norstein; T J Eide; H E Myrvold; O Søreide
Journal:  Br J Surg       Date:  2002-03       Impact factor: 6.939

2.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

3.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

4.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

5.  A concordance correlation coefficient to evaluate reproducibility.

Authors:  L I Lin
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

6.  Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial.

Authors:  Matthew H G Katz; Nipun B Merchant; Steven Brower; Megan Branda; Mitchell C Posner; L William Traverso; Ross A Abrams; Vincent J Picozzi; Peter W T Pisters
Journal:  Ann Surg Oncol       Date:  2010-09-01       Impact factor: 5.344

7.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

8.  Long-term survival and recurrence outcomes following surgery for distal rectal cancer.

Authors:  Eric J Silberfein; Kiran M Kattepogu; Chung-Yuan Hu; John M Skibber; Miguel A Rodriguez-Bigas; Barry Feig; Prajnan Das; Sunil Krishnan; Christopher Crane; Scott Kopetz; Cathy Eng; George J Chang
Journal:  Ann Surg Oncol       Date:  2010-06-15       Impact factor: 5.344

9.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

10.  Division of the right posterior attachments of the head of the pancreas with a linear stapler during pancreaticoduodenectomy: vascular and oncological considerations based on an anatomical cadaver-based study.

Authors:  Patrick Baqué; Antonio Iannelli; Jérome Delotte; Fernand de Peretti; André Bourgeon
Journal:  Surg Radiol Anat       Date:  2008-08-19       Impact factor: 1.246

View more
  28 in total

Review 1.  Surgical management of pancreatic neoplasms: what's new?

Authors:  Andreas Karachristos; Nestor F Esnaola
Journal:  Curr Gastroenterol Rep       Date:  2014-08

2.  Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer.

Authors:  Hop S Tran Cao; Alpana Balachandran; Huamin Wang; Graciela M Nogueras-González; Christina E Bailey; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans; Gauri Varadhachary; Christopher H Crane; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2013-10-16       Impact factor: 3.452

Review 3.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

4.  Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality.

Authors:  Jason W Denbo; Morgan L Bruno; Jordan M Cloyd; Laura Prakash; Jeffrey E Lee; Michael Kim; Christopher H Crane; Eugene J Koay; Sunil Krishnan; Prajnan Das; Bruce D Minsky; Gauri Varadhachary; Rachna Shroff; Robert Wolff; Milind Javle; Michael J Overman; David Fogelman; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2016-10-11       Impact factor: 3.452

5.  Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma.

Authors:  Alexandra Snyder; Peter Allen; Ali Shamseddine; Ali Haydar; Mohamed Eloubeidi; Walid Faraj; Mohamed Khalife; Sally Temraz; Ashwaq El-Olayan; David P Kelsen; Fadi El-Merhi; Mohamed Naghy; Leonard B Saltz; Ghassan K Abou-Alfa; Eileen M O'Reilly
Journal:  Gastrointest Cancer Res       Date:  2012-09

6.  Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens.

Authors:  Jean Robert Delpero; Philippe Bachellier; Nicolas Regenet; Yves Patrice Le Treut; François Paye; Nicolas Carrere; Alain Sauvanet; Aurélie Autret; Olivier Turrini; Geneviève Monges-Ranchin; Jean Marie Boher
Journal:  HPB (Oxford)       Date:  2013-03-07       Impact factor: 3.647

7.  Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.

Authors:  Jordan M Cloyd; Christopher H Crane; Eugene J Koay; Prajnan Das; Sunil Krishnan; Laura Prakash; Rebecca A Snyder; Gauri R Varadhachary; Robert A Wolff; Milind Javle; Rachna T Shroff; David Fogelman; Michael Overman; Huamin Wang; Anirban Maitra; Jeffrey E Lee; Jason B Fleming; Matthew H G Katz
Journal:  Cancer       Date:  2016-05-31       Impact factor: 6.860

8.  Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques.

Authors:  Matthew H G Katz; Jeffrey E Lee; Peter W T Pisters; Roman Skoracki; Eric Tamm; Jason B Fleming
Journal:  J Am Coll Surg       Date:  2012-08       Impact factor: 6.113

9.  Combined hepatic arterial resection in pancreatic resections for locally advanced pancreatic cancer.

Authors:  Masaru Miyazaki; Hideyuki Yoshitomi; Shigetsugu Takano; Hiroaki Shimizu; Atsushi Kato; Hiroyuki Yoshidome; Katunori Furukawa; Tsukasa Takayashiki; Satoshi Kuboki; Daisuke Suzuki; Nozomu Sakai; Masayuki Ohtuka
Journal:  Langenbecks Arch Surg       Date:  2017-03-30       Impact factor: 3.445

10.  Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base.

Authors:  Lauren E Colbert; William A Hall; Dana Nickleach; Jeffrey Switchenko; David A Kooby; Yuan Liu; Theresa Gillespie; Joseph Lipscomb; John Kauh; Jerome C Landry
Journal:  Cancer       Date:  2014-01-03       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.